Association Between Retroperitoneal Lymphadenectomy and Survival Benefit in the Endometrioid-Type Endometrial Carcinoma Patients

Background: Uterine cancer stays the most prevalent gynecologic malignancy in developed countries. Providing suitable solutions to treat this disease is required to the early diagnosis of this cancer. Objectives: The aim of this study was to evaluate the effectiveness of multiple-site lymph node sampling in patients with the endometrioid type of endometrial cancer. Patients and Methods: Demographic and clinicopathologic data were obtained from the Tehran Gynecology Oncology ward in Vali-e-Asr Hospital between 1999 and 2010. All the patients were divided into two groups. Group A (n = 102): patients who underwent multiple-site lymph node sampling; and Group B (n = 102): patients who did not undergo multiple-site lymph node sampling. Survival curves were calculated using the Kaplan-Meier method, and the differences in survival rates were analyzed using the log-rank test. Results: The median age was 55 years (range = 18 - 84). The 5-year progression-free survival rates of Groups A and B were 85% and 87%, respectively (P = 0.456). In addition, the 5-year overall survival rates were 95% and 93.9%, respectively (P = 0.651). Subsequently, there was no significant difference in recurrence rates in retroperitoneal lymph nodes regardless of the completion of lymphadenectomy. Conclusions: The obtained data showed no evidence of benefit in terms of overall or recurrence-free survival for pelvic lymphadenectomy in women with early endometrial cancer.